Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.
We compared the activities of linezolid (25 mg/kg of body weight, administered intraperitoneally every 8 h) and of vancomycin (25 mg/kg of body weight, administered intraperitoneally every 8 h) in a rat model of vanA vancomycin-resistant Enterococcus faecium experimental endocarditis. Results were expressed as median log(10) CFU per gram of vegetation after 3 days of treatment. The median log(10) CFU per gram of vegetation was 10.1 among 7 untreated control animals, 10.2 among 9 vancomycin-treated animals, and 7.9 among 10 linezolid-treated animals. Linezolid treatment was more active (P < 0.05) than vancomycin treatment or no treatment.
Patel
R
R
Division of Infectious Diseases and Infectious Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. patel.robin@mayo.edu
Rouse
M S
MS
Piper
K E
KE
Steckelberg
J M
JM
D000081:Acetamides / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000235:genetics; D019729:Carbon-Oxygen Ligases / Q000235:genetics; D004352:Drug Resistance, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D016984:Enterococcus faecium / Q000187:drug effects* / Q000235:genetics; D005838:Genotype; D000069349:Linezolid; D008297:Male; D023303:Oxazolidinones / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D020713:Vancomycin Resistance / Q000235:genetics*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D023303:Oxazolidinones; C071437:VanA ligase, Bacteria; D019729:Carbon-Oxygen Ligases; D000069349:Linezolid